Can nuclear medicine help with a rising PSA post radical treatment?

Author(s): Dr Brent Drake, Dr Thomas Gruning, Dr Peter Sankey, Dr Asha Omar

Hospital: The Royal Marsden Hospital; Derriford Hospital; University Hospitals Plymouth NHS Trust

Reference: RAD Magazine, 48, 570, 26-27


Nuclear medicine imaging has always played an important role in the management of patients with prostate cancer, both pre and post therapy. This has primarily been through the use of conventional gamma camera imaging and bone scans for the detection of metastatic bone disease for which prostate cancer has a predilection. The role of nuclear medicine has seen recent, rapid evolution and expansion in this patient group, both because of enhanced imaging techniques for these conventional bone tracers which improve sensitivity and specificity (eg whole body single photon emission computed tomography [SPECT] and SPECT/CT) and, more recently, by the development and burgeoning availability of PET tracers.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more